Literature DB >> 23773558

Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?

Günter Niegisch1, Anja Lorch, Michael J Droller, Hugh J Lavery, Kristian D Stensland, Peter Albers.   

Abstract

Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 23773558     DOI： 10.1016/j.eururo.2013.06.002

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  16 in total

1.  A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy.

Authors:  Ettore Di Trapani; Rafael Sanchez-Salas; Giorgio Gandaglia; Lorenzo Rocchini; Marco Moschini; Daphne Lizee; Arie Carneiro; Arjun Sivaraman; Eric Barret; François Rozet; Marc Galiano; Mostefa Bennamoun; Renzo Colombo; Nazareno Suardi; Alberto Briganti; Francesco Montorsi; Xavier Cathelineau
Journal:  World J Urol       Date:  2015-07-22       Impact factor: 4.226

2.  Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?

Authors:  Günter Niegisch
Journal:  Transl Androl Urol       Date:  2019-07

3.  A Festschrift in Honor of Edward M. Messing, MD, FACS.

Authors:  Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump
Journal:  Bladder Cancer       Date:  2018-10-03

4.  Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Authors:  Homayoun Zargar; Patrick N Espiritu; Adrian S Fairey; Laura S Mertens; Colin P Dinney; Maria C Mir; Laura-Maria Krabbe; Michael S Cookson; Niels-Erik Jacobsen; Nilay M Gandhi; Joshua Griffin; Jeffrey S Montgomery; Nikhil Vasdev; Evan Y Yu; David Youssef; Evanguelos Xylinas; Nicholas J Campain; Wassim Kassouf; Marc A Dall'Era; Jo-An Seah; Cesar E Ercole; Simon Horenblas; Srikala S Sridhar; John S McGrath; Jonathan Aning; Shahrokh F Shariat; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeff M Holzbeierlein; Trinity J Bivalacqua; Scott North; Daniel A Barocas; Yair Lotan; Jorge A Garcia; Andrew J Stephenson; Jay B Shah; Bas W van Rhijn; Siamak Daneshmand; Philippe E Spiess; Peter C Black
Journal:  Eur Urol       Date:  2014-09-23       Impact factor: 20.096

5.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.

Authors:  Antonina V Kurtova; Jing Xiao; Qianxing Mo; Senthil Pazhanisamy; Ross Krasnow; Seth P Lerner; Fengju Chen; Terrence T Roh; Erica Lay; Philip Levy Ho; Keith Syson Chan
Journal:  Nature       Date:  2014-12-03       Impact factor: 49.962

Review 6.  The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.

Authors:  Christopher E Barbieri; Arul M Chinnaiyan; Seth P Lerner; Charles Swanton; Mark A Rubin
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

7.  Defining the potential of neoadjuvant chemotherapy use as a quality indicator for bladder cancer care.

Authors:  Goutham Vemana; Kenneth G Nepple; Joel Vetter; Gurdarshan Sandhu; Seth A Strope
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

8.  Scoring system for prediction of lymph node metastasis in radical cystectomy cohort.

Authors:  Miroslav M Stojadinović; Rade Prelević; Arso Vukićević
Journal:  Int Urol Nephrol       Date:  2014-01-29       Impact factor: 2.370

9.  Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience.

Authors:  Gry Assam Taarnhøj; Henriette Lindberg; Christoffer Johansen; Helle Pappot
Journal:  J Clin Med       Date:  2021-04-24       Impact factor: 4.241

10.  Expression of Vitamin D Receptor (VDR) Positively Correlates with Survival of Urothelial Bladder Cancer Patients.

Authors:  Wojciech Jóźwicki; Anna A Brożyna; Jerzy Siekiera; Andrzej T Slominski
Journal:  Int J Mol Sci       Date:  2015-10-15       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.